Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity.
Animals
Antiviral Agents
/ chemical synthesis
Dose-Response Relationship, Drug
Drug Discovery
Enzyme Inhibitors
/ chemical synthesis
Female
Male
Mice
Mice, Inbred Strains
Microbial Sensitivity Tests
Molecular Structure
Neuraminidase
/ antagonists & inhibitors
Orthomyxoviridae
/ drug effects
Oseltamivir
/ analogs & derivatives
Structure-Activity Relationship
150-Cavity
Influenza virus
Neuraminidase inhibitors
Oseltamivir derivatives
Journal
European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510
Informations de publication
Date de publication:
15 Feb 2021
15 Feb 2021
Historique:
received:
19
08
2020
revised:
08
12
2020
accepted:
08
12
2020
pubmed:
2
1
2021
medline:
24
4
2021
entrez:
1
1
2021
Statut:
ppublish
Résumé
Encouraged by our earlier discovery of N1-selective inhibitors, the 150-cavity of influenza virus neuraminidases (NAs) could be further exploited to yield more potent oseltamivir derivatives. Herein, we report the design, synthesis and biological evaluation of a series of novel oseltamivir derivatives via the structural modifications at C
Identifiants
pubmed: 33385836
pii: S0223-5234(20)31069-2
doi: 10.1016/j.ejmech.2020.113097
pii:
doi:
Substances chimiques
Antiviral Agents
0
Enzyme Inhibitors
0
Oseltamivir
20O93L6F9H
Neuraminidase
EC 3.2.1.18
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
113097Informations de copyright
Copyright © 2020 Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare no conflict of interest.